Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 54Leukemia, Myeloid, Acute 53Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Myeloproliferative Disorders 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Non-Hodgkin 19Leukemia, Myelomonocytic, Chronic 16Primary Myelofibrosis 13Leukemia 11Hodgkin Disease 11Sarcoma 9Polycythemia Vera 9Neuroblastoma 9Histiocytosis, Langerhans-Cell 9Glioma 9Wilms Tumor 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Medulloblastoma 8Leukemia, Biphenotypic, Acute 8Hepatoblastoma 8Ependymoma 8Anemia, Refractory, with Excess of Blasts 8Thrombocythemia, Essential 7Rhabdomyosarcoma 7Osteosarcoma 7Myelodysplastic-Myeloproliferative Diseases 7Blast Crisis 7Multiple Myeloma 6Blastic Plasmacytoid Dendritic Cell Neoplasm 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polycythemia × Myeloid × 30 days × Clear all
NCT07527221 2026-06-01

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Eilean Therapeutics

Phase 1 Recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡